We
previously reported that N-(3-chlorophenyl)guanidine
(1) represents a novel α7 nicotinic ACh (nACh)
receptor antagonist chemotype. In the present study, a small series
of compounds was synthesized with the intent to investigate the structure–activity
relationship (SAR). Preliminary data suggested that the N-methyl analog
of 1, 2, was several times more potent.
Therefore, the chloro group at the aryl 3-position of 1 and its N1-methyl counterpart 2 were replaced
with a number of substituents considering the electronic, lipophilic,
and steric nature of the substituents. The potencies of the compounds
to inhibit acetylcholine (ACh)-induced responses were obtained in Xenopus laevis oocytes expressing human α7 nicotinic
ACh receptors (nAChRs) using a two-electrode voltage-clamp assay.
We found that the nature of the 3-position substituents had relatively
little (i.e., <10-fold) effect on potency, and the presence of
an N1-isopropyl substituent was tolerated. Here, we report
the first SAR investigation of this novel α7 nAChR antagonist
chemotype.